Partner with Jefferson

BioVaxys is a clinical-stage biopharmaceutical company developing technology based on the pioneering work of Jefferson researchers. The company currently has multiple product candidates in its pipeline, ranging from Phase II clinical trials to preclinical development. Its programs focus on cancer immunotherapies, infectious diseases, and allergies. BioVaxys is distinguished by the application of its Haptenix© technology platform to train the immune system to recognize and aggressively target tumor and viral proteins. 

Bound Therapeutics is a preclinical-stage biotechnology company advancing Jefferson-discovered nucleic acid-based therapeutics RNA inhibitors for triple negative breast cancer towards clinic. Bound Therapeutics’ pipeline has also expanded to include lungs, colon, prostate and brain cancers.

Capillary Biomedical was a clinical-stage Jefferson medical device startup developing technologies for diabetes management and sustained insulin release. Capillary was acquired by and became a subsidiary of Tandem Diabetes Care Inc. in 2022, which advanced their program to the SteadiSet^TM infusion set, which received FDA clearance in July of 2025. Their research was funded by the Juvenile Diabetes Research Association. 

Clementia Pharmaceuticals was a clinical-stage biopharmaceutical company developing a Jefferson-discovered use of palovarotene, a retinoic acid receptor gamma agonist, in the treatment of fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder which causes extra-skeletal bone formation in muscle and soft tissues. Clementia was acquired by the French drug maker Ipsen in 2019, which advanced the programs to commercialization as Sohonos^TM, the first approved therapy for FOP (approval dates as of Oct 2025, US 2023, Canada, Australia and Russia 2024). 

Immunome is a clinical-stage oncology company developing antibody-based therapies that target novel antigen-antibody pairs identified from patients’ immune responses to their own tumors. The company originated from technology jointly created at Thomas Jefferson University and the MIT Whitehead Institute, securing Series A funding in 2016 and 2017. Immunome continues to expand its pipeline of targeted cancer therapies through internal research and strategic in-licensing of complementary programs from external partners. The company began trading on the Nasdaq in October 2020.

ImTol is a preclinical stage biotechnology company advancing first-in-class treatments for autoimmune diseases based on a novel therapeutic platform developed at Jefferson. ImTol’s lead product candidate is designed to treat multiple sclerosis (MS) by selectively targeting all pathogenic sells while avoiding systemic immunosuppression. This treatment is active against all forms of MS and has the potential to stop its progression, including the Progressive MS. Additionally, ImTol’s pipeline includes selective treatments for two major and one orphan autoimmune diseases.

Imax is a clinical-stage biotechnology company developing personalized, tumor-derived immunotherapies invented by Jefferson researchers and clinicians. In December 2025, the company announced the results from its Phase IIb trial of IGV-001 to treat newly diagnosed glioblastoma multiform, the deadliest of brain cancers. IGV-001 has increased median overall survival by 6.3 months or 45% over that achieved with the current standard of care, which has not changed in the last 20 years. Imvax has raised over $235 million in funding across multiple rounds, including a large Series C financing in 2020 and additional capital raised from existing investors in 2024 and 2025. 

KOP Therapeutics is a preclinical-biotechnology company focused on the development of novel RNA-based cancer therapies discovered by Jefferson researchers. KOP’s antisense oligonucleotide (AON) therapy is designed to “silence” pathways critical to cancer cell nourishment.  As of October 2025, KOP has validated its AON therapy in prostate, breast, brain and ovarian cancer cells in addition to showing tumor reduction and inhibition in mice with prostate cancer tumors. 

NuView Life Sciences is a clinical-stage radiopharmaceutical company developing next-generation products for both the diagnosis and treatment of cancer based on technology invented at Jefferson. Its proprietary platform NV-VPAC1^TM targets vasoactive peptide type 1 receptor (VPAC1) for diagnosis and treatment of cancers such as prostate, breast, brain and pancreatic. The NV-VPAC1^TM test is currently undergoing clinical trials to determine its suitability as a non-invasive diagnostic for prostate cancer.

Prostagene was a clinical-stage biotechnology company developing cancer therapeutics targeting CCR5 for the prevention of metastasis in many types of cancers based on research conducted in Jefferson laboratories. In 2018 the company was acquired by CytoDyn Inc., which continues developing Prostagen’s PRO 140 (leronlimab) technology as a therapeutic for metastatic cancers such as colorectal and triple-negative breast cancer (TNBC).

RTM Vital Signs is a clinical-stage Jefferson spinout developing wearable devices that use artificial intelligence and acoustic technology to provide continuous, real-time monitoring of patient vital signs. RTM Vital Signs received Fast Track Designation from the FDA in 2020 and the company's first-generation Respiratory Monitoring System (RMS) was granted 510(k) clearance by the FDA in July 2025.

Sempresto, launched in 2024, is commercializing a disruptive smartphone-integrated autoinjector system specifically designed to address one of the most persistent gaps in emergency care: ensuring that lifesaving medications are always on hand when needed most. Nearly two-thirds of patients experiencing severe allergic reactions arrive at the Emergency Department without having received epinephrine beforehand. The size, inconvenience, and forgettability of traditional autoinjectors remain major barriers to timely use. Sempresto’s solution is a slim, smartphone-mounted epinephrine autoinjector which integrates seamlessly into daily life. By attaching directly to the one item most people carry everywhere, the device is designed to eliminate the most common barriers to proper utilization and significantly improve a patient’s access to their rescue medicine when they need it.

Sonogen is working to commercialize a next generation ultrasonic bone fracture healing and monitoring device. Under a Phase I STTR grant from the National Science Foundation Sonogen collaborated with Thomas Jefferson University to demonstrate that its device is highly effective for bone fracture healing. Sonogen has received seed investments from TEDCO and Ecphora to support its research and development efforts and is currently seeking Series A investments to finalize the design, build, and clinical validation of its commercial device.

Veralox Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapeutics that target the underlying pathologies of serious immuno-inflammatory diseases. Co-developed through a multi-institutional collaboration of Jefferson, National Institutes of Health (NIH), Eastern Virginia Medical School and University of California, Veralox’s lead drug candidate is VLX-1005  is currently in a Phase 2 clinical study for  the treatment of heparin-induced thrombocytopenia (HIT), a life-threatening rare immune-mediated disease. It has been granted Fast Track and Orphan Drug designations by the FDA, as well as Orphan Drug Status by the EMA. A second-generation product is also in development for type 1 diabetes. Veralox received grant funding, from the US Department of Health and Human Services and has raised over $40M across multiple rounds including a $5.4 million seed round in 2019 co-led by several investors including Sanofi Ventures, the JDRF T1D Fund, a $16.6 million Series A led by Hatteras Venture Partners in 2021 and a  $24 million Series B round led by Pappas Capital and NYBC Ventures in 2023.

Xilio is a clinical-stage biopharmaceutical company formed around technology for tumor-activated oncology therapies designed to treat cancer while minimizing severe systemic side effects, licensed from Jefferson and the City of Hope. The company’s tumor-selective immunotherapies maximize the potency of immuno-oncology therapies and minimize peripheral side effects by restricting their activity to the tumors. Xilio Therapeutics currently has multiple products in its pipeline ranging from clinical stage (Phase 1/2) to preclinical development. Xilio Therapeutics completed an Initial Public Offering in October 2021 and a public offering of pre-funded and common stock warrants in June 2025. Before its 2021 IPO, Xilio Therapeutics raised significant capital through several private funding rounds including a Series A co-led by F-Prime Capital and Atlas Venture, a $100.5 million Series B led by Takeda Ventures: a $95 million Series C led by Rock Springs Capital.